Abcuro
Jay Knowles joined Mass General Brigham Ventures in 2014 as a Partner. Previously, Jay was CEO of X-BODY Biosciences (acquired by Juno). Prior to X-BODY, he was at Novartis in charge of the Platforms team for Strategic Alliances, responsible for global technology and drug discovery collaborations. Jay was also President of Novalar, Vice President of Business Development at Novacea, and Director, R&D Planning at Vertex Pharmaceuticals. He earned his MBA in Finance from Wharton Business School, an M.Sc. in Chemistry from UC Berkeley, and a BA with Distinction in Chemistry from Carleton College. He represents Partners on the boards of Apres, Keros (KROS), ROME, Swan, and Triplet. Previous recent investments include Akouos (AKUS), Denali (DNLI), Editas (EDIT), Tilos (acquired by Merck), and Translate (TBIO).
This person is not in the org chart
This person is not in any offices
Abcuro
2 followers
Abcuro is a clinical stage biotechnology company developing treatments for autoimmune and cancer indications modulated by cytotoxic T and NK cells that express the inhibitory immune checkpoint receptor KLRG1 (killer cell lectin-like receptor G1). The company is advancing ABC008, a first-in-class anti-KLRG1 antibody designed to deplete cytotoxic T cells that attack healthy muscle tissue in patients with inclusion body myositis (IBM), into clinical studies.